*  Organ, tissue donors give 2nd chance at life

... eye and tissue donor today.. In California:. Donate LIFE California , Done VIDA California. Nationwide:. Organ Donor , Donate ... Donate Life Texas Living Kidney Donation living kidney donor Second Chance at Life ...
donatelife-organdonation.blogspot.com/2016/03/organ-tissue-donors-give-2nd-chance-at.html

*  April is National Donate Life Organ & Tissue Donor Awareness Month | | The Rock River Times

Tissue Donor Awareness Month By Kay Coles James, Director U.S. Office of Personnel Management The gift of life is the ... You can find information and even download an organ/tissue donor card and sign up to become a donor. Remember, giving and ... April is National Donate Life Organ & Tissue Donor Awareness Month Jul 1, 1993. Staff ... April is National Donate Life Organ & Tissue Donor Awareness Month. By Kay Coles James, Director U.S. Office of Personnel ...
rockrivertimes.com/1993/07/01/april-is-national-donate-life-organ-tissue-donor-awareness-month/

*  Am I A Tissue Donor, Too? | WUKY

Part 3 in a four-part series Maybe you've agreed to be an organ donor. There might be something on your driver's license - a ... SIMINOFF: It just means you're - it means you're a donor. It means you're a tissue and an organ donor. ... "It means you're a donor," she says. "And it means you're a tissue and an organ donor." ... Am I A Tissue Donor, Too? By Joseph Shapiro • Jul 18, 2012 ... So am I a tissue donor? SIMINOFF: Yeah, you should be - because ...
wuky.org/post/am-i-tissue-donor-too

*  ACRMC host flag raising to honor organ, eye, and tissue donors - People's Defender

He also encouraged others to register to be organ, eye and tissue donors. ... eye and tissue donors. LifeCenter's Executive Director, Barry Massa thanked the ACRMC staff for their commitment to donation ... Waits then released a single balloon in honor of his donor.. Locally, more than 600 people are on the waiting for an organ ... LifeCenter's mission is to save, enhance and change lives through organ and tissue donation. LifeCenter is a non-profit organ ...
peoplesdefender.com/2016/04/27/acrmc-host-flag-raising-to-honor-organ-eye-and-tissue-donors/

*  Organ & Tissue Donor Registration Links Worldwide: Worldwide Organ Donor Registration Links

One tissue donor can help by donating skin, corneas, bone, tendon, ligaments and heart valves ... Organs can save lives, corneas renew vision, and tissue may help to restore someone's ability to walk, run or move freely ... Am now an advocate for Organ & Tissue transplantation and research. Email me. View my complete profile ... is added to the national transplant waiting list every 11 minutes and 18 people die each day waiting for an organ or tissue ...
worldwidedonorlinks.blogspot.com/2013/06/worldwide-organ-donor-registration-links.html

*  4 Reasons to Tell Your Family That You're a Registered Organ & Tissue Donor - LifeCenter

Making the decision to become an organ & tissue donor is a very personal one, but it has the potential to affect the lives of ... Letting your family know that you have decided to be a registered organ and tissue donor will help clear up any potential ... When you register as a donor, you are essentially granting legal authorization for your organs and tissues to be recovered and ... You never really know how your selfless decision to become an organ and tissue donor might change another family member or ...
lifepassiton.org/4-reasons-tell-family-youre-registered-organ-tissue-donor/

*  Connecticut - Anatomical Gifts (Organ And Tissue Donors)

Most active law and legislation in Connecticut
statesurge.com/states/connecticut/anatomical-gifts-organ-and-tissue-donors-56827

*  Barbara Workman, Tissue Donor - LifeCenter

My mother's name was Barbara Workman, and Mom was the center of our entire family. She was the one to organize family get-togethers with our aunts, uncles, and cousins, and she was the one who never had a bad thing to say to or about anyone. Everyone adored my mom.. She was a very sick woman but continued to play an important role in her Eastern Stars family and in ours. Mom had a bad valve in her heart, and she had gone through two valve replacement surgeries but was too weak to withstand another surgery. She pushed herself for almost nine years before her heart just gave out.. My mom knew I worked with kidney transplant patients and wanted to donate "anything they could use," so when she passed, we were able to donate her corneas and inner ear. Now, because of her, there are two people who can see and hear again. This calendar is so special to me because we are able to honor Mom's legacy and the wonderful gifts she gave.. December 10, 2011, will be the 13th anniversary of losing my precious ...
lifepassiton.org/barbara-workman-tissue-donor/

*  Writing Letters to the Family of an Organ and Tissue Donor - Gift of Life Donor Program

Information for organ transplant recipients who choose to write a letter to the families of their donors. ... please e-mail us or call Family Support Services at 800-DONORS-1.. Find Related Info. Donors, Family Services, Organ Donors, ... Writing to Your Donor's Family. As a transplant recipient, you have the opportunity to write to the family of your donor ... We know that donor families appreciate hearing from recipients. Remember the donor family may still be coping with the loss of ...
donors1.org/patient/writing/

*  How can I become an organ and tissue donor? - Answered by top doctors on HealthTap

Organ transplantation and tissue typing. Do I have to be related to my tissue matching organ donor? ... Organ transplantation and tissue typing. Do I have to be related to my tissue matching organ donor? ... Organ transplantation and tissue typing. Am i related to my tissue matching organ donor? ... can b more Are there organ transplants can be rejected by the body if the donor tissue is too different from the host. can bone ...
https://healthtap.com/user_questions/8559-how-can-i-become-an-organ-and-tissue-donor

*  Where Does Donor Tissue Come From for Plastic Surgery? Doctor Answers, Tips

Alloderm is a tissue matrix from allogenic dermis. This means it comes from the dermis of someone other than the recipient. ... Are they from any deceased organ donor? How about the tissue used to create a tissue matrix like AlloDerm? Hoping to shine some ... After coming across an article on MMA fighters getting tissue implants from donors, I'm curious to know where the cadavers come ... but I am certain that either the donor or a family member has given permission to use this tissue. The skin is an considered an ...
https://realself.com/question/donor-tissue

*  A Biosynthetic Alternative to Human Donor Tissue for Inducing Corneal Regeneration: 24-Month Follow-Up of a Phase 1 Clinical...

Research ArticleTissue Engineering. A Biosynthetic Alternative to Human Donor Tissue for Inducing Corneal Regeneration: 24- ... with the aim of facilitating endogenous tissue regeneration without the use of human donor tissue. The biosynthetic implants ... Corneas from human donors are used to replace damaged tissue and treat corneal blindness, but there is a severe worldwide ... A Biosynthetic Alternative to Human Donor Tissue for Inducing Corneal Regeneration: 24-Month Follow-Up of a Phase 1 Clinical ...
stm.sciencemag.org/content/2/46/46ra61

*  Providence Honors Organ and Tissue Donors and Families at Annual Rose Dedication Ceremony | Providence Health & Services...

Providence Honors Organ and Tissue Donors and Families at Annual Rose Dedication Ceremony ... "Our donor families make it possible to save lives or vastly improve the lives of the sick and injured who receive donor organs ... Providence Honors Organ and Tissue Donors and Families at Annual Rose Dedication Ceremony. October 30, 2013 ... Providence Honors Organ and Tissue Donors and Families at Annual Rose Dedication Ceremony ...
california.providence.org/news/2013/10/providence-honors-organ-and-tissue-donors-and-families-at-annual-rose-dedication-ceremony/

*  Tissue Transplants and Tissue Donation - Gift of Life Donor Program

... bone transplants and tissue donation - Gift of Life Donor Program ... Register today to be an organ and tissue donor.. Find Related ... The gift of donated tissue can help many people in a variety of ways and the stories of lives changed by generous donors are ... How Does the Donor Program Work?. Gift of Life Donor Program works with hospitals and families throughout the region to help ... Tissue Donation. While many people are familiar with the idea of organ donation, tissue donation is not as familiar, but is no ...
donors1.org/learn2/organs/tissue/

*  Public Health Service Inter-Agency Guidelines for Screening Donors of Blood, Plasma, Organs, Tissues, and Semen for Evidence

Organ or tissue procurement organizations should report this information to the donor's physician when the donor is deceased. ... Organ or tissue procurement organizations should report this information to the donor's physician when the donor is deceased. ... or have received untested tissue or tissue from an HBsAg-positive donor, and prophylaxis with hepatitis B immune globulin and ... provider that they will or have received untested tissue or tissue from an anti-HCV repeatedly reactive donor. ...
https://cdc.gov/mmwr/preview/mmwrhtml/00043883.htm

*  Media Releases - Organ and Tissue Donation and Transplantation - Gift of Life Donor Program

Press releases documenting news and happenings at Gift of Life Donor Program. ... Delaware continues to be at the forefront in its commitment to registering organ and tissue donors, expanding the donor pool ... How Does the Donor Program Work?. Gift of Life Donor Program works with hospitals and families throughout the region to help ... and Patricia Nelson informed Gift of Life Donor Program that their son had already made the decision to be an organ and tissue ...
donors1.org/about-us/media/press1/

*  Donation procedure | Imperial College London

... friends and professionals to help the Multiple Sclerosis and Parkinson's Tissue Bank collect tissue from registered donors. ... friends and professionals to help the Multiple Sclerosis and Parkinson's Tissue Bank collect tissue from registered donors. ... Brain and spinal cord tissues deteriorate very rapidly. We aim to collect tissue within 24 hours of death and can accept tissue ... The donor's name and donor card number. If your message is received between 9am and 5pm, Monday-Sunday, the brain bank will be ...
imperial.ac.uk/medicine/multiple-sclerosis-and-parkinsons-tissue-bank/brain-donors/donation-procedure/

*  Organs and Tissues That Can Be Transplanted - Gift of Life Donor Program

Gift of Life Donor Program is the region's nonprofit organ donation program serving Philadelphia, Pennsylvania, New Jersey and ... The gift of donated tissue can help many people in a variety of ways and the stories of lives changed by generous donors are ... Tissue Donation. While many people are familiar with the idea of organ donation, tissue donation is not as familiar, but is no ... Since 1974, Gift of Life Donor Program has helped hundreds of thousands of patients through organ and tissue donation. ...
donors1.org/learn2/organs/

*  Mitochondrial-associated cell death mechanisms are reset to an embryonic-like state in aged donor-derived iPS cells harboring...

Tissue Donors*. Comments/Corrections. From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine ... Four iPSC lines were generated from dermal fibroblasts derived from an 84-year-old woman, representing the oldest human donor ... Mitochondrial-associated cell death mechanisms are reset to an embryonic-like state in aged donor-derived iPS cells harboring ... in a similar fashion as iPSCs derived from young donors and hESCs. Thus, the occurrence of chromosomal abnormalities within ...
biomedsearch.com/nih/Mitochondrial-Associated-Cell-Death-Mechanisms/22110631.html

*  Anti-Rat Nestin Antibody, clone Rat-401 (4D4) - Mouse Anti-Rat Monoclonal Antibody WB, IHC-P, IHC-F, IF - Buy Now! |Abgent

Tissue Selections. Abgent offers a variety of tissue extracts and whole cell lysates for use in combination with our antibodies ... or E7 induces prolongation of the life span of bone marrow stromal cells from an elderly donor without affecting their ... Cell Tissue Res. 337: 27-36. 6. Shin, Y.J. et al. (2010) Enhanced expression of vascular endothelial growth factor receptor-3 ... Nestin expression has also been noted in other embryonic tissues, also in most Glioblastoma multiformes and many melanomas. ...
abgent.com/products/ABD10658-Anti-Rat-Nestin-Antibody-clone-Rat-401-4D4-

*  MEG3 Gene - GeneCards | MEG3 RNA Gene

Protein tissue co-expression partners , mRNA Expression by UniProt/SwissProt , Evidence on tissue expression from TISSUES and ... CRISPR: plasmid gRNA, lentiviral gRNA, and donor plasmid. *Bacterial expression: pET, pBAD, and pCS ... This gene is expressed in many normal tissues, but its expression is lost in multiple cancer cell lines of various tissue ... mRNA expression in normal human tissues from GTEx, Illumina, BioGPS, and CGAP SAGE for MEG3 Gene. ...
genecards.org/cgi-bin/carddisp.pl?gene=MEG3&pubmed=35

*  Human Metabolome Database: Showing metabocard for TG(16:1(9Z)/18:1(9Z)/20:4(5Z,8Z,11Z,14Z)) (HMDB0005441)

In adipose tissue and heart, it primarily hydrolyzes stored triglycerides to free fatty acids, while in steroidogenic tissues, ... Hydrogen Donor Count. 0. ChemAxon. Polar Surface Area. 78.9 Ų. ChemAxon. Rotatable Bond Count. 50. ChemAxon. ... is the precursor for TAG synthesis in adipose tissue. DHAP can also serve as a TAG precursor in non-adipose tissues, but does ... Tissue Location. Not Available. Pathways. Name. SMPDB/Pathwhiz. KEGG. De Novo Triacylglycerol Biosynthesis TG(16:1(9Z)/18:1(9Z ...
hmdb.ca/metabolites/HMDB05441

*  GC10P043432 Gene - GeneCards | GC10P043432 RNA Gene

Protein tissue co-expression partners , mRNA Expression by UniProt/SwissProt , Evidence on tissue expression from TISSUES and ... CRISPR: plasmid gRNA, lentiviral gRNA, and donor plasmid. *Bacterial expression: pET, pBAD, and pCS ... No data available for mRNA expression in normal human tissues , mRNA expression in embryonic tissues and stem cells from ... LifeMap Discovery , mRNA differential expression in normal tissues , Protein differential expression in normal tissues , ...
genecards.org/cgi-bin/carddisp.pl?gene=GC10P043432

*  In Vitro Fertilization | Blake Medical Center | Bradenton, FL

Penile scar tissue or other conditions may block the natural release of sperm. If this is the case, a sperm aspiration from the ... If the male partner is unable to produce viable sperm, donor sperm may be used. If male sperm counts are low, the chance of ...
https://blakemedicalcenter.com/hl/?/14826/In-Vitro-Fertilization&com.dotmarketing.htmlpage.language=1

*  NewYork-Presbyterian/Queens - Glossary - Women's Center

autologous tissue breast reconstruction - the use of the patient's own tissues to reconstruct a new breast mound. The common ... The location where the skin is removed is called the donor site. There are various types of skin grafts that may be utilized, ... hyperplasia - an abnormal increase in the number of cells in a tissue or an organ (i.e., cervix or the lining of the uterus). ... tissue expansion - a surgical procedure that involves inserting a balloon-like device (called an expander) under the skin. The ...
nyhq.org/diw/Content.asp?PageID=DIW006683&More=WTN&language=Spanish

(1/3426) Effect of MTHFR 677C>T on plasma total homocysteine levels in renal graft recipients.

BACKGROUND: Hyperhomocysteinemia is an established, independent risk factor for vascular disease morbidity and mortality. The 5,10-methylenetetrahydrofolate reductase (MTHFR) gene polymorphism C677T has been shown to result in increased total homocysteine concentrations on the basis of low folate levels caused by a decreased enzyme activity. The effect of this polymorphism on total homocysteine and folate plasma levels in renal transplant patients is unknown. METHODS: We screened 636 kidney graft recipients for the presence of the MTHFR C677T gene polymorphism. The major determinants of total homocysteine and folate plasma concentrations of 63 patients, who were identified to be homozygous for this gene polymorphism compared with heterozygotes (N = 63), and patients with wild-type alleles (N = 63), who were matched for sex, age, glomerular filtration rate (GFR), and body mass index, were identified by analysis of covariance. The variables included sex, age, GFR, body mass index, time since transplantation, folate and vitamin B12 levels, the use of azathioprine, and the MTHFR genotype. To investigate the impact of the kidney donor MTHFR genotype on total homocysteine and folate plasma concentrations, a similar model was applied in 111 kidney graft recipients with stable graft function, in whom the kidney donor C677T MTHFR gene polymorphism was determined. RESULTS: The allele frequency of the C677T polymorphism in the MTHFR gene was 0.313 in the whole study population [wild-type (CC), 301; heterozygous (CT), 272; and homozygous mutant (TT), 63 patients, respectively] and showed no difference in the patient subgroups with various renal diseases. The MTHFR C677T gene polymorphism significantly influenced total homocysteine and folate plasma concentrations in renal transplant recipients (P = 0.0009 and P = 0.0002, respectively). Furthermore, a significant influence of the GFR (P = 0.0001), folate levels (P = 0.0001), age (P = 0.0001), body mass index (P = 0.0001), gender (P = 0.0005), and vitamin B12 levels (P = 0.004) on total homocysteine concentrations was observed. The donor MTHFR gene polymorphism had no influence on total homocysteine and folate levels. Geometric mean total homocysteine levels in patients homozygous for the mutant MTHFR allele were 18.6 micromol/liter compared with 14.6 micromol/liter and 14.9 micromol/liter in patients heterozygous for the MTHFR gene polymorphism and those with wild-type alleles (P < 0.05 for TT vs. CT and CC). Geometric mean folate levels were lower in CT and TT patients (11.2 and 10.2 nmol/liter) compared with CC patients (13.6 nmol/liter, P < 0.05 vs. CT and TT). CONCLUSIONS: This study demonstrates that homozygosity for the C677T polymorphism in the MTHFR gene significantly increases total homocysteine concentrations and lowers folate levels in kidney graft recipients, even in patients with excellent renal function (GFR more than median). These findings have important implications for risk evaluation and vitamin intervention therapy in these patients who carry an increased risk for the development of cardiovascular disease.  (+info)

(2/3426) A prospective, randomized trial of tacrolimus/prednisone versus tacrolimus/prednisone/mycophenolate mofetil in renal transplant recipients.

BACKGROUND: Between September 20, 1995 and September 20, 1997, 208 adult patients undergoing renal transplantation were randomized to receive tacrolimus/prednisone (n=106) or tacrolimus/prednisone/mycophenolate mofetil (n=102), with the goal of reducing the incidence of rejection. METHODS: The mean recipient age was 50.7+/-13.7 years. Sixty-three (30.3%) patients were 60 years of age or older at the time of transplantation. The mean donor age was 34.5+/-21.7 years. The mean cold ischemia time was 30.5+/-9.2 hr. The mean follow-up is 15+/-7 months. RESULTS: The overall 1-year actuarial patient survival was 94%; the overall 1-year actuarial graft survival was 87%. When the patient and graft survival data were stratified to recipients under the age of 60 who did not have delayed graft function, the overall 1-year actuarial patient survival was 97%, and the corresponding 1-year actuarial graft survival was 93%. There were no differences between the two groups. The overall incidence of rejection was 36%; in the double-therapy group, it was 44%, whereas in the triple therapy group, it was 27% (P=0.014). The mean serum creatinine was 1.6+/-0.8 mg/dl. A total of 36% of the successfully transplanted patients were taken off prednisone; 32% of the patients were taken off antihypertensive medications. The incidence of delayed graft function was 21%, the incidence of cytomegalovirus was 12.5%, and the initial and final incidences of posttransplant insulin-dependent diabetes mellitus were 7.0% and 2.9%; again, there was no difference between the two groups. CONCLUSIONS: This trial suggests that the combination of tacrolimus, steroids, and mycophenolate mofetil is associated with excellent patient and graft survival and a lower incidence of rejection than the combination of tacrolimus and steroids.  (+info)

(3/3426) Pediatric renal transplantation under tacrolimus-based immunosuppression.

BACKGROUND: Tacrolimus has been used as a primary immunosuppressive agent in adult and pediatric renal transplant recipients, with reasonable outcomes. Methods. Between December 14, 1989 and December 31, 1996, 82 pediatric renal transplantations alone were performed under tacrolimus-based immunosuppression without induction anti-lymphocyte antibody therapy. Patients undergoing concomitant or prior liver and/or intestinal transplantation were not included in the analysis. The mean recipient age was 10.6+/-5.2 years (range: 0.7-17.9). Eighteen (22%) cases were repeat transplantations, and 6 (7%) were in patients with panel-reactive antibody levels over 40%. Thirty-four (41%) cases were with living donors, and 48 (59%) were with cadaveric donors. The mean donor age was 27.3+/-14.6 years (range: 0.7-50), and the mean cold ischemia time in the cadaveric cases was 26.5+/-8.8 hr. The mean number of HLA matches and mismatches was 2.8+/-1.2 and 2.9+/-1.3; there were five (6%) O-Ag mismatches. The mean follow-up was 4.0+/-0.2 years. RESULTS: The 1- and 4-year actuarial patient survival was 99% and 94%. The 1- and 4-year actuarial graft survival was 98% and 84%. The mean serum creatinine was 1.1+/-0.5 mg/dl, and the corresponding calculated creatinine clearance was 88+/-25 ml/min/1.73 m2. A total of 66% of successfully transplanted patients were withdrawn from prednisone. In children who were withdrawn from steroids, the mean standard deviation height scores (Z-score) at the time of transplantation and at 1 and 4 years were -2.3+/-2.0, -1.7+/-1.0, and +0.36+/-1.5. Eighty-six percent of successfully transplanted patients were not taking anti-hypertensive medications. The incidence of acute rejection was 44%; between December 1989 and December 1993, it was 63%, and between January 1994 and December 1996, it was 23% (P=0.0003). The incidence of steroid-resistant rejection was 5%. The incidence of delayed graft function was 5%, and 2% of patients required dialysis within 1 week of transplantation. The incidence of cytomegalovirus was 13%; between December 1989 and December 1992, it was 17%, and between January 1993 and December 1996, it was 12%. The incidence of early Epstein-Barr virus-related posttransplant lymphoproliferative disorder (PTLD) was 9%; between December 1989 and December 1992, it was 17%, and between January 1993 and December 1996, it was 4%. All of the early PTLD cases were treated successfully with temporary cessation of immunosuppression and institution of antiviral therapy, without patient or graft loss. CONCLUSIONS: These data demonstrate the short- and medium-term efficacy of tacrolimus-based immunosuppression in pediatric renal transplant recipients, with reasonable patient and graft survival, routine achievement of steroid and anti-hypertensive medication withdrawal, gratifying increases in growth, and, with further experience, a decreasing incidence of both rejection and PTLD.  (+info)

(4/3426) Split liver transplantation.

OBJECTIVE: This study reviews the indications, technical aspects, and experience with ex vivo and in situ split liver transplantation. BACKGROUND: The shortage of cadaveric donor livers is the most significant factor inhibiting further application of liver transplantation for patients with end-stage liver disease. Pediatric recipients, although they represent only 15% to 20% of the liver transplant registrants, suffer the greatest from the scarcity of size-matched cadaveric organs. Split liver transplantation provides an ideal means to expand the donor pool for both children and adults. METHODS: This review describes the evolution of split liver transplantation from reduced liver transplantation and living-related liver transplantation. The two types of split liver transplantation, ex vivo and in situ, are compared and contrasted, including the technique, selection of patients for each procedure, and the most current results. RESULTS: Ex vivo splitting of the liver is performed on the bench after removal from the cadaver. It is usually divided into two grafts: segments 2 and 3 for children, and segments 4 to 8 for adults. Since 1990, 349 ex vivo grafts have been reported. Until recently, graft and patient survival rates have been lower and postoperative complication rates higher in ex vivo split grafts than in whole organ cadaveric transplantation. Further, the use of ex vivo split grafts has been relegated to the elective adult patient because of the high incidence of graft dysfunction (right graft) when placed in an emergent patient. Reasons for the poor function of ex vivo splits except in elective patients have focused on graft damage due to prolonged cold ischemia times and rewarming during the long benching procedure. In situ liver splitting is accomplished in a manner identical to the living donor procurement. This technique for liver splitting results in the same graft types as in the ex vivo technique. However, graft and patient survival rates reported for in situ split livers have exceeded 85% and 90%, respectively, with a lower incidence of postoperative complications, including biliary and reoperation for bleeding. These improved results have also been observed in the urgent patient. CONCLUSION: Splitting of the cadaveric liver expands the donor pool of organs and may eliminate the need for living-related donation for children. Recent experience with the ex vivo technique, if applied to elective patients, results in patient and graft survival rates comparable to whole-organ transplantation, although postoperative complication rates are higher. In situ splitting provides two grafts of optimal quality that can be applied to the entire spectrum of transplant recipients: it is the method of choice for expanding the cadaver liver donor pool.  (+info)

(5/3426) High-risk donors: expanding donor criteria.

Advances in the surgical techniques, preservation solutions, and methods for predicting eventual long-term renal function from expanded donors will be critical in allowing precise selection criteria for kidneys for transplantation, resulting in the optimum use of a scarce and precious resource. Until other options such as xenotransplantation or tissue engineering become realistic, the challenge for the millennium will be to identify which donor organs previously considered suboptimal can be safely used to expand the organ donor pool.  (+info)

(6/3426) Correction of bone marrow failure in dyskeratosis congenita by bone marrow transplantation.

Dyskeratosis congenita is recognized by its dermal lesions and constitutional aplastic anemia in some cases. We report successful allogeneic bone marrow transplantation in two siblings with this disease from their sister, and their long term follow-up. We used reduced doses of cyclophosphamide and busulfan for conditioning instead of total body irradiation. Also, we report late adverse effects of transplantation which are not distinguishable from the natural course of disease.  (+info)

(7/3426) Relaxin secretion by human granulosa cell culture is predictive of in-vitro fertilization-embryo transfer success.

We have developed a cell culture system for human luteinizing granulosa cells which supports the timely and dynamic secretion of oestrogen, progesterone and relaxin in patterns that mimic serum concentrations of these hormones during the luteal phase of the menstrual cycle. There was a wide variation in the amount of relaxin secreted by the cultured cells for the 69 patients studied. As relaxin production was generally maximal by day 10 of culture, comparisons were made at this time point. It was observed that most of the conceptions occurred in patients with higher relaxin secretion in vitro. All cycles with relaxin > 800 pg/ml on day 10 had a term pregnancy while only 13% of cycles with relaxin < 200 pg/ml had term pregnancies. A limited number of cycles from donor/recipient cycles did not show similar results. Steroid concentrations were not predictive of conception. These results demonstrated that in-vitro production of relaxin is predictive of implantation success in in-vitro fertilization (IVF)-embryo transfer cycles. This supports the hypothesis that relaxin may be involved in implantation and that lowered relaxin concentrations may be a partial cause of poor pregnancy rates after IVF.  (+info)

(8/3426) Short-term toxicity in pediatric marrow transplantation using related and unrelated donors.

The use of volunteer, unrelated donors has substantially increased the number of potential donors for pediatric marrow transplantation during the past few years. We describe our single institution experience of short-term toxicity after pediatric marrow transplantation using sibling or unrelated donors. Fully matched (A, B and DR loci) donors were employed in 94% of the cases in both groups. Conditioning of similar intensity and uniform supportive care were employed in the two groups. Both primary non-engraftment and secondary graft failure were more common among recipients of unmanipulated URD grafts. Clinically significant (grades III-IV) acute GVHD and toxic mortality during the immediate post-transplant period were also higher in this group of patients. Pediatric marrow transplantation using volunteer, unrelated donors appears to be associated with an increased incidence of procedure-related toxic complications.  (+info)



cancer


  • Giving total-body irradiation before a donor peripheral blood stem cell transplant helps stop the growth of cells in the bone marrow, including normal blood-forming cells (stem cells) and cancer cells. (clinicaltrials.gov)